MDACC Study No:2013-0583 ( NCT No: NCT02003573)
Title:An Open Label, Phase I/IIa, Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Volasertib in Combination with Decitabine in Patients >/= 65 Years with Acute Myeloid Leukemia
Principal Investigator:Jorge Cortes
Treatment Agent:Volasertib
Study Status:Closed
Study Description:The goal of Phase 1 of this study is to find the highest tolerable dose of
volasertib combined with DacogenŽ (decitabine) that can be given to patients
with AML. The safety and level of effectiveness of this drug combination will
also be studied.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I/Phase II
Treatment Agents:Volasertib
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Boehringer Ingelheim Pharmaceuticals, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jorge Cortes
For Clinical Trial Enrollment:713-794-5783
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults